Humacyte (NASDAQ:HUMA) Receives Buy Rating from D. Boral Capital

AI Briefing

• – D. Boral Capital upgrades Humacyte to Buy, sets $25.00 target price.
• – Weiss Ratings reissues Sell rating on Humacyte.
• – Humacyte shares have been the topic of several other research reports.